Pill vs chemo before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This study compares taking a daily pill (dalpiciclib with hormone therapy) versus standard chemotherapy before breast cancer surgery. It's for postmenopausal women with a common type of early breast cancer that is strongly hormone-receptor positive and HER2-negative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a postmenopausal woman (no period for at least a year).
- Your breast cancer must be strongly ER-positive (at least 50% of cells test positive for estrogen receptors) and HER2-negative.
- Your cancer must be at an early stage (T1-3, N1, M0) meaning it may have spread to 1–3 lymph nodes but not to other organs.
- You must not have had any breast cancer treatment before, including chemotherapy, hormone therapy, or surgery (except a diagnostic biopsy).
- Your heart and lung function must be generally healthy—no serious heart disease, uncontrolled lung problems, or recent heart attack.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
This trial tests a combination of three drugs (dalpiciclib, letrozole, and anlotinib) given before surgery to postmenopausal women with stage II or III HR+/HER2- breast cancer. The goal is to see if this neoadjuvant treatment shrinks tumors and improves outcomes.
This trial tests if women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy after surgery by taking targeted medication (ribociclib) plus hormone therapy. A special blood test called ctDNA helps doctors decide if chemo isn't needed.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.